囊性纤维化患者在使用依伐卡托、泰它卡托和艾氟康唑治疗前后的硫酸脱氢表雄酮（DHEA-S）浓度。
Concentrations of dehydroepiandrosterone-sulphate (DHEA-S) in people with cystic fibrosis on and off elexacaftor-tezacaftor-ivacaftor.
机构信息
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, PN 19104, USA.
出版信息
J Cyst Fibros. 2024 Sep;23(5):874-877. doi: 10.1016/j.jcf.2024.04.007. Epub 2024 Apr 22.
BACKGROUND
Levels of sulfated Dehydroepiandrosterone (DHEA-S) are unknown in people with Cystic Fibrosis (pwCF). DHEA-S is reported to have an inverse association with inflammation and warrants evaluation in pwCF.
METHODS
We compared differences in DHEA-S and other hormones between pwCF (n = 180) and without CF (n = 180) and DHEA-S association with percent predicted forced expiratory volume in one second (ppFEV1). We also evaluated DHEA-S levels in people with CF on elexacaftor-tezacaftor-ivacaftor (ETI) (n = 145).
RESULTS
PwCF (not on ETI) had lower DHEA-S levels compared to healthy non-CF controls. DHEA-S levels in individuals with CF on ETI were similar to those without CF. Lower DHEA-S levels were associated with lower ppFEV1.
CONCLUSIONS
PwCF (not on ETI) have lower levels of DHEA-S than people without CF or people with CF on ETI. Additional studies are needed to investigate the impact of DHEA-S on the health of pwCF and mechanisms involved.
背景
囊性纤维化（CF）患者的硫酸去氢表雄酮（DHEA-S）水平未知。有报道称 DHEA-S 与炎症呈负相关，值得在 CF 患者中进行评估。
方法
我们比较了 CF 患者（n=180）和非 CF 患者（n=180）之间 DHEA-S 和其他激素的差异，以及 DHEA-S 与预计用力呼气量的百分比（ppFEV1）的相关性。我们还评估了接受 elexacaftor-tezacaftor-ivacaftor（ETI）治疗的 CF 患者（n=145）的 DHEA-S 水平。
结果
未接受 ETI 治疗的 CF 患者的 DHEA-S 水平低于健康的非 CF 对照组。接受 ETI 治疗的 CF 患者的 DHEA-S 水平与非 CF 患者相似。较低的 DHEA-S 水平与较低的 ppFEV1 相关。
结论
未接受 ETI 治疗的 CF 患者的 DHEA-S 水平低于非 CF 患者或接受 ETI 治疗的 CF 患者。需要进一步研究 DHEA-S 对 CF 患者健康的影响及其相关机制。
Zotero 插件